Evidera operates as a wholly owned subsidiary of Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO). Evidera was created in 2013 as an independent company under the ownership of Symphony Technology Group (STG) following the acquisition of long-standing health economics, outcomes research, market access, epidemiology and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group and Archimedes. Since it was formed, Evidera has worked with all of the top 20 biopharma companies, and is a preferred provider for most of the top 50. Evidera scientists and consultants publish more than 150 peer-reviewed articles per year and have more than 1,100 studies in progress across all major therapeutic areas. Evidera’s 300 researchers and consultants have expertise working in all developed and many developing countries.
Bethesda, US
Evidera was founded in 2013 and is headquartered in Bethesda, US
Report incorrect company information

Evidera Office Locations

Evidera has an office in London, Budapest, Bethesda, Harrisburg and in 4 other locations
Bethesda, US (HQ)
1400 7101 Wisconsin Ave
Harrisburg, US
503 225 Market St
San Francisco, US
650 450 Sansome St
Seattle, US
510 1417 4th Ave
Waltham, US
500 Totten Pond Rd
Montréal, CA
Route Transcanadienne
Show all (8)
Report incorrect company information

Evidera Financials and Metrics

Summary Metrics

Founding Date

Report incorrect company information

Evidera News and Updates

Biosimulation Market is Projected to Reach US$ 1,750 Mn by 2022

The global biosimulation market is forecasted to reach a figure of about US$ 1,750 Mn in 2022 and is poised to exhibit a robust CAGR in the period of assessment. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information